专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1123110A1 COMPOSITIONS AND METHODS FOR PROMOTING TISSUE REPAIR USING HEAT SHOCK PROTEINS 审中-公开
标题翻译：组合物和方法用于促进组织再生使用的热休克蛋白
公开(公告)号：EP1123110A1
公开(公告)日：2001-08-16
申请号：EP99953222.9
申请日：1999-10-19
申请人： Fordham University
发明人： SRIVASTAVA, Pramod, K. , CHANDAWARKAR, Rajiv, Y.
IPC分类号： A61K38/16
CPC分类号： A61K38/1709 , A61K2300/00
摘要： The invention relates to methods and compositions for the promotion of tissue repair. Specifically, compositions comprising heat shock proteins, including gp96, hsp90, and hsp70, uncomplexed or complexed noncovalently with antigenic molecules, are disclosed. Therapeutic methods for administering the hsp-containing compositions are disclosed. The disclosed methods are useful for promoting repair of tissues that were disrupted by a variety of causes including trauma (e.g., surgery, injury or burns) or disease or disorder (e.g., atherosclerosis and multiple sclerosis).

2. 发明公开

EP1218030A1 METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GRAFT REJECTION USING HEAT SHOCK PROTEINS 审中-公开
标题翻译：方法和组合物可用于治疗和移植预防热休克蛋白的使用
公开(公告)号：EP1218030A1
公开(公告)日：2002-07-03
申请号：EP00961701.0
申请日：2000-09-08
申请人： Fordham University
发明人： SRIVASTAVA, Pramod, K. , CHANDAWARKAR, Rajiv, Y.
IPC分类号： A61K39/385 , A61K45/00 , A01N37/18 , C07K1/00 , C07K2/00
CPC分类号： A61K39/001 , A61K2039/6043 , A61K2039/622
摘要： Methods for treatment and prevention of graft rejection, e.g., in response to tissue or organ transplantation, are disclosed. The disclosed methods comprise administration of compositions of complexes of heat shock/stress protein (hsps) including, but not limited to, hsp70, hsp90, and gp96, either alone or in combination with each other, noncovalently bound to antigenic molecules, to suppress the immune response to the grafted tissue or organ. In addition, administration of compositions containing un-complexed stress proteins (i.e., free of antigenic molecules) to suppress the immune response to the grafted tissue or organ are also disclosed. The invention encompasses administration of heat shock proteins before, after, or both before and after transplantation or grafting. In addition, the invention encompasses administration of donor tissue sample prior to administration of heat shock protein and subsequent transplantation or grafting.

3. 发明申请

WO2001017554A1 METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GRAFT REJECTION USING HEAT SHOCK PROTEINS 审中-公开
标题翻译：治疗和预防使用热休克蛋白抑制剂的方法和组合物
公开(公告)号：WO2001017554A1
公开(公告)日：2001-03-15
申请号：PCT/US2000/024711
申请日：2000-09-08
申请人： FORDHAM UNIVERSITY , SRIVASTAVA, Pramod, K. , CHANDAWARKAR, Rajiv, Y.
发明人： SRIVASTAVA, Pramod, K. , CHANDAWARKAR, Rajiv, Y.
IPC分类号： A61K39/385
CPC分类号： A61K39/001 , A61K2039/6043 , A61K2039/622
摘要： Methods for treatment and prevention of graft rejection, e.g., in response to tissue or organ transplantation, are disclosed. The disclosed methods comprise administration of compositions of complexes of heat shock/stress protein (hsps) including, but not limited to, hsp70, hsp90, and gp96, either alone or in combination with each other, noncovalently bound to antigenic molecules, to suppress the immune response to the grafted tissue or organ. In addition, administration of compositions containing un-complexed stress proteins (i.e., free of antigenic molecules) to suppress the immune response to the grafted tissue or organ are also disclosed. The invention encompasses administration of heat shock proteins before, after, or both before and after transplantation or grafting. In addition, the invention encompasses administration of donor tissue sample prior to administration of heat shock protein and subsequent transplantation or grafting.
摘要翻译：公开了用于治疗和预防移植排斥反应的方法，例如响应于组织或器官移植。所公开的方法包括非共价结合抗原分子的单独或彼此组合的包括但不限于hsp70，hsp90和gp96的热休克/应激蛋白（hsps）复合物的组合物，以抑制对移植组织或器官的免疫应答。此外，还公开了含有非复合应激蛋白（即，不含抗原性分子）的组合物的给药以抑制对移植组织或器官的免疫应答。本发明包括在移植或移植之前，之后或之前施用热休克蛋白。此外，本发明包括在给予热休克蛋白之前施用供体组织样品，随后进行移植或移植。

4. 发明公开

EP1024701A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASE USING HEAT SHOCK PROTEINS 审中-公开
标题翻译：的方法和手段用于自身免疫性疾病的治疗中使用的热休克蛋白
公开(公告)号：EP1024701A1
公开(公告)日：2000-08-09
申请号：EP98953509.1
申请日：1998-10-14
申请人： Fordham University
发明人： SRIVASTAVA, Pramod, K. , CHANDAWARKAR, Rajiv, Y.
IPC分类号： A01N63/00 , A61K45/05 , A61K39/00 , A61K38/17
CPC分类号： A61K38/1709 , Y10S424/81 , Y10S514/825 , Y10S514/866 , Y10S514/903 , Y10S530/806 , Y10S530/827 , Y10S530/868
摘要： The invention relates to methods and compositions for the treatment of autoimmune disease. Specifically, compositions comprising heat shock proteins, including gp96, hsp90, and hsp70, are disclosed. Immunotherapeutic methods for administering the hsp-containing compositions are disclosed. Furthermore, methods for preventing rejection of organs transplanted to treat autoimmune disease are disclosed. The disclosed methods are useful for treating a variety of autoimmune diseases, including insulin dependent diabetes mellitus.

5. 发明公开

EP0973548A1 PREVENTION AND TREATMENT OF PRIMARY AND METASTATIC NEOPLASTIC DISEASES AND INFECTIOUS DISEASES WITH HEAT SHOCK/STRESS PROTEIN-PEPTIDE COMPLEXES 失效
标题翻译：预防和初级和转移性肿瘤性疾病治疗和手段INFEKRIONSKRANKHEITEN热休克/应激蛋白复合
公开(公告)号：EP0973548A1
公开(公告)日：2000-01-26
申请号：EP98906153.6
申请日：1998-02-03
申请人： Fordham University
发明人： SRIVASTAVA, Pramod, K. , CHANDAWARKAR, Rajiv, Y.
IPC分类号： A61K39/385 , A61K45/05 , A01N63/00 , C07K14/435
CPC分类号： A61K39/0011 , A61K2039/6043 , A61K2039/622 , Y02A50/466
摘要： The present invention relates to methods and compositions for eliciting an immune response and the prevention-and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式